A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
← catalyst calendarSponsored by Erasca, Inc. (industry) · ERAS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
86actual
Sites
29
Countries
Australia, Canada, South Korea +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-17 | actual | When the study began enrolling |
| Primary completion | 2025-07-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic Solid Tumors
Interventions
- Drug: Naporafenib — also filed as LXH254, ERAS-254
- Drug: Trametinib — also filed as Mekinist
Primary outcome
what the primary-completion date above is the date OFTo evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors
measured Assessed up to 24 months from time of first dose
Permalink · ERAS's whole pipeline · Catalyst calendar · Every registered study · What changed